SUMMARY C3 degradation products (C3dg/d) were estimated in 288 synovial fluid (SF) samples (rheumatoid arthritis (RA) 93, osteoarthritis (OA) 68, chronic pyrophosphate arthropathy 80, acute pseudogout 20, others 27) from knees of 138 patients (bilateral 67, serial sampling on two to six occasions 40). At each aspiration knees were defined as 'active' or 'inactive' by single observer global assessment using six clinical parameters of inflammation. Lack of correlation between paired SF and plasma C3dg/d implied local C3 activation within joints. Raised SF C3d levels were found in active compared with inactive RA joints (mean (range) 51 (15-105) and 6 (0-15) units/ml respectively). Low SF C3dg/d levels were found in OA (mean (range) 0-8 (0-7) units/ml) and chronic pyrophosphate arthropathy (mean (range) 4 (0-16) units/ml), irrespective of clinical activity. In contrast, very high levels (mean (range) 61 (16-126) units/ml) were present in all cases of pseudogout. These differences remained after correction for SF C3 or albumin. This study is the first to show a positive correlation between SF C3dg/d and local inflammation in RA joints. It further suggests that C3 activation is a constant feature of pseudogout but not an accompaniment of inflammation associated with chronic crystal associated synovitis or OA.
Complement activation by both classical and alternative pathways is thought to play an important part in mediation of inflammation in a variety of rheumatic diseases. [1] [2] [3] [4] [5] [6] [7] Evidence to support such a role includes (a) in vitro activation of complement by factors such as immune complexes,8 rheumatoid factors,9 10 and monosodium urate and calcium pyrophosphate dihydrate (CPPD) crystals '1-13 and (b) direct demonstration of complement activation in blood and synovial fluid (SF) of patients with rheumatic disease. [1] [2] [3] [4] [5] [6] [7] Although complement activation in rheumatic diseases has [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Only two studies, however, have attempted to characterise the clinical activity of the joints aspirated, and in these reports, including 40 patients with rheumatoid arthritis2l and 10 with juvenile chronic arthritis,26 no apparent correlation was observed between SF complement activation and the clinical state of the joint. The relation between complement activation and local joint inflammation, therefore, remains in question. 21 24 In this study we estimated complement degradation products with C3d specificity (C3dg/d27-hereafter abbreviated as C3d) together Table 3 ; the lower number of plasma samples (221) relates to frequent bilateral knee sampling on the same occasion.
Comparison between groups showed raised plasma C3d levels only in seropositive RA patients (p<0-01). Correction for C3 (i.e., the plasma C3d/C3 quotient4 31) more clearly delineated the raised level found in this group (Table 3) .
Comparison between major groups for SF C3d showed markedly raised levels in seropositive RA (p<0.001), seronegative RA (p<0-001), and pseudogout (p<0.001) compared with the very low levels in OA (Table 3) ; a modest, but highly significant, increase was seen in CPA (p<0001). The highest levels were seen in pseudogout (mean (range) 61 (16-126) units/ml). In the other, smaller groups a moderate increase of SF C3d was seen in acute Reiter's disease (p<0.01), psoriatic arthritis (p<0-01), and in the three patients with acute gout; levels in chronic gout were similar to those in CPA. Correction for SF C3 did not significantly alter these between group comparisons but emphasised the increases seen in seropositive RA, pseudogout, and acute gout (Table 3) . Correction for SF albumin similarly did not alter the differences between groups but emphasised the increases seen in pseudogout and seropositive RA (Table 3) .
No correlation was observed between plasma and SF C3d levels either overall (r=0-44) or within the seropositive RA group alone (r=0-40). The Table 4 ; comparable data for groups requiring no division (i.e., pseudogout, acute gout, Reiter's disease-all joints active; chronic gout-all joints inactive) are contained in Table 3 . Individual SF C3d values are shown in Fig. 1 .
I
Markedly raised SF C3d levels were found in active compared with inactive RA joints, irrespective of seropositivity (p<0O001 both groups). No difference in SF C3d, however, was observed between active or inactive OA, or between active and inactive CPA; compared with active OA, SF C3d remained significantly raised in both active (p<0-001) and inactive (p<0-001) CPA knees. In contrast with active CPA, markedly raised SF C3d levels were seen in all cases ofpseudogout (p<0-001).
Compared with pyrophosphate arthropathy, a less impressive difference in SF C3d was observed between the small number of patients with acute (active) and chronic (inactive) gout (Fig. 1) . SF C3d levels in active psoriatic arthropathy were comparable with those in acute Reiter's disease (Fig. 1) .
SF C3d IN BILATERAL AND SERIAL SAMPLES
Twelve patients with RA underwent simultaneous bilateral sampling at a time when their knees showed contrasting clinical activities. Comparison between the two sides in these patients showed marked differences in SF C3d, with higher levels in the active knee (Fig. 2) . Simultaneous bilateral sampling of 18 patients with RA and clinically OA CPA R A similar knees (Fig. 2) activation is therefore ideally based on detection of activation products or on turnover studies. In the present study evidence of complement activation, by either classical or alternative pathway, was sought by estimation of stable breakdown products of C3 with C3d specificity (C3dg/d) using an established rocket immunoelectrophoresis system.27 As the C3d/C3 ratio may be a more reliable indicator of complement activation than C3d alone,4 31 this quotient was additionally determined.
As in previous studies4 5 23 25 a marked increase of SF C3d was shown in certain disease categories. That such an increase represents local activation of complement within joints24 25 was supported by the lack of correlation between plasma and SF C3d, the markedly higher C3d values observed in SF, and the frequently marked variation in SF C3d levels between different joints of the same individual. As the concentration of serum proteins in SF varies considerably the albumin concentration was used to correct absolute C3d to relative values, thereby permitting comparison of SF results between different groups. It was not necessary, however, to correct between different groups. It was also unnecessary to correct for protein content in order to show local complement activation in SF (owing to the frequently much higher values in SF than in plasma), and correction for SF albumin made little difference to intergroup or within group comparisons. Similarly, because no group showed marked depression of SF C3, comparison of the corrected C3d/C3 quotient,4 31 though to some extent sharpening division between categories, did not substantially alter findings derived from comparison of SF C3d alone.
The results of the between group comparisons are in substantial agreement with previous SF complement studies in showing no evidence for complement activation in OA,1 3-6 16 18 20 21 24 but significant activation in RA16 14-25 (particularly those with seropositive disease,1 3 6 15) and acute pseudogout.6 14 15 18 24 This is the first study to examine CPA as a separate major diagnostic group, and the finding of a modest but significant increase of SF C3d in CPA compared with OA has not previously been reported. SF complement activation has previously been demonstrated in psoriatic arthropathy15 16 21 25 and acute Reiter's disease,1 6 16 21 25 and the only unexpected finding was the comparatively modest increase of SF C3d in the three cases of acute gout. 6 14 16 18 24 Although possibly explained by the small sample numbers or inappropriate timing of aspiration after onset of the acute attack, this finding is consistent with the suggested minor role for complement activation in acute gouty inflammation. 16 21 36 The major findings of this study, however, relate to division within each diagnostic group according to the local clinical inflammatory activity of the aspirated joint. There is no generally agreed system for clinical assessment of 'joint inflammation', and any division into active or inactive is necessarily arbitrary and an inevitable compromise. The six clinical parameters employed, however, may reasonably be expected to reflect predominantly inflammatory activity, rather than mechanical damage or periarticular injury, in the disease states examined, and for the purposes of the present study a single observer and a summated score were used with exclusion of joints that were intermediate between the two extremes of the scoring range. Further grading, other than into active or inactive, was not attempted. Such clinical characterisation would seem essential to any study that investigates mediators of inflammation in joint tissues. Surprisingly, however, only two SF complement studies have previously addressed this issue and attempted to define aspirated joints in both clinical and diagnostic terms. Sheppeard et al graded clinical activity of knees as mild, moderate, or severe according to the degree of pain, swelling, warmth, and tenderness,21 whereas Mollnes and Paus used a functional knee score (0-100) devised for outcome assessment of RA knees after synovectomy.26 Pain, unspecified tenderness, restriction of movement, deformity, and instability, however, do not necessarily reflect the presence of synovitis, and inappropriate clinical assessment may in part explain the failure of either study to show correlation between SF complement activation and clinical activity.
In the present study markedly raised SF C3d levels were seen in active compared with inactive RA joints, and serial sampling showed that SF C3d levels vary in concert with inflammatory activity. To our knowledge this is the first study to show a positive correlation between SF complement activation and local, clinically assessed inflammation in RA joints. A similar correlation was suggested in the two smaller seronegative spondarthritis groups in this study.
Seropositive and seronegative RA patients were considered separately as rheumatoid factors have been shown to activate complement in vitro,9 10 and positive correlation between rheumatoid factor and complement activation has been shown in plasma37 and in certain SF studies1 2 6 of patients with RA. The present finding of a higher mean level of SF C3d in seropositive patients as a group appears to support a possible role for rheumatoid factor in complement activation.1 10 Comparison of SF C3d in active joints alone, however, as in certain previous reports,5 21 25 showed no clear relation between seropositivity and complement activation, thus emphasising the importance of clinical and diagnostic characterisation. The cause(s) or pathways of complement activation in RA, however, were not the subject of the present study and cannot be deduced from the data.
Comparison of SF C3d findings in OA, CPA, and pseudogout was of special interest. Although OA joints are commonly used as 'non-inflammatory' disease controls in SF studies, 1 
